1 / 21

Nanomedicine: Revolutionizing Healthcare

Explore the cutting-edge field of nanomedicine, which applies nanotechnology to improve prevention, diagnosis, and treatment of diseases. This vision document presents the potential impact and advancements in nanomedicine.

Télécharger la présentation

Nanomedicine: Revolutionizing Healthcare

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. La Nanomedicina Prof. Dr. Josep Samitier Univ. De Barcelona Lab Nanobioingeniería (IBEC) Coordinador Plataforma Española de Nanomedicina Director Adjunto CIBER BBN

  2. Informe FENIN 2006 Biotecnologia

  3. Nuevas Tecnologías Miniaturización Técnicas clásicas (Macro) Microdispositivos Nanotecnología Convergencia de tecnologías Richard Feynman

  4. Given Imaging Ltd Comercial

  5. Definition: NanoMedicine, for the purpose of this vision document, is defined as the application of Nanotechnology to Health. It exploits the improved and often novel physical, chemical, and biological properties of materials at the nanometric scale. NanoMedicine has potential impact on the prevention, early and reliable diagnosis and treatment of diseases.

  6. NIH Nanomedicine Roadmap Initiative, emprendida por el Instituto Nacional de Salud de EE.UU en mayo de 2004 (http://www.capconcorp.com/roadmap04/) ESF Scientific Forward Look on Nanomedicine, presentado por el comité de expertos de la European Science Foundation en febrero de 2005 (http://www.esf.org/newsrelease/83/SPB23Nanomedicine.pdf) EuroNanoForum 2005, Nanotechnology and the Health of the EU Citizen in 2020 (Edimburgo, 6 – 9 septiembre de 2005). Entorn internacional

  7. (2006)

  8. PRESENTACIÓN DEL INFORME PLATAFORMA ESPAÑOLA DE NANOMEDICINA

  9. PLATAFORMA ESPAÑOLA DE NANOMEDICINA Jornadas de Plataformas Tecnológicas Josep Samitier Parc Científic de Barcelona-Univ. de Barcelona Institut de Bioenginyeria de Catalunya (IBEC)

  10. MIEMBROS 108 grupos diferentes

  11. GRUPOS DE TRABAJO • Nanodiagnóstico • Medicina Regenerativa • Liberación de Fármacos • Educación / Comunicación • Toxicidad / Regulación

  12. MIEMBROS Por Comunidades Autónomas

  13. EURONANOBIO WP1 Experts Workshop Nanobio Clusters: identifying best practices Dr Arantxa Sanz Prof. Josep Samitier Institute for Bioengineering of Catalonia (IBEC) Barcelona, SPAIN

  14. WP1:OBJECTIVES AND METHOD GLOBAL OBJECTIVE: Identifying best practices across the most successful clusters As integration is key to success in nanobio, success = high quality, common research projects and results (with diverse cluster members as partners) DATA COLLECTION and ANALYSIS: METHODOLOGY (Feb-May 09) • Definition of a nanobio cluster in the study: research vs innovation cluster • Mapping clusters elsewhere: USA, Canada, Asia-Pacific • Mapping clusters in Europe • Identifying best practices via SWOT analysis • Consolidation workshop: discussion and brainstorming

  15. Clinical Research Innovation Cluster agency Cluster agency non specific USA: mapping preliminary results BAY AREA SOUTH CALIFORNIA HOUSTON CHICAGO BOSTON CORNELL N. CAROLINA …

  16. Clinical Research Innovation Cluster agency Cluster agency non specific ASIA PACIFIC – preliminary results TSUKUBA / TOKYO KOBE YONSEI (SEOUL) SINGAPORE SIDNEY …

  17. Clinical Research Innovation Cluster agency Cluster agency non specific European Union: mapping preliminary results Most advanced nanobio clusters across EU + associate states: -Higher integration level of actors, including hospitals -Remarkable common output in terms of funded projects, research papers and patents / creation of spin off companies

  18. SWOT analysis: Applying criteria for case studies HOUSTON

  19. SWOT analysis for the mapped clusters (some examples…) MÜNSTER – EXAMPLE

More Related